Skip to main content

Table 4 Response rate (RR) by radiologic (preoperative; 6 weeks from baseline) and histologic (6–8 weeks from baseline) assessments

From: Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

  All patients (N = 28) Ipi 3 mg/kg (n = 14) Ipi 10 mg/kg (n = 14)
No. pts. % No. pts. % No. pts. %
Radiologic preoperative RR (WHO; unconfirmed) 10 (9 PR, 1CR) 36% 4 (3 PR, 1 CR) 29 6 (All PR) 43
Pathologic complete RR (no viable tumor on histologic assessment) 9 32% 5 36 4 29
Among radiologic responders
• One relapsed and later responded to anti-PD1 antibody therapy
Among complete pathologic responders
• None relapsed to date